Oncology
Lymphoid Malignancies
0
Pipeline Programs↗
7
Active Trials↗
10
Companies Involved↗
Lymphoid Malignancies is an early-stage landscape with 0 programs across 10 companies. The most active players are PersonGen BioTherapeutics (Suzhou) Co., Ltd., Sunesis Pharmaceuticals, Gilead.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
50
clinical trials
Completed29 · 58%
Terminated8 · 16%
Recruiting6 · 12%
Unknown status5 · 10%
Active, not recruiting1 · 2%
Withdrawn1 · 2%
Clinical Trials
Trial Activity
50 trials
Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
Recruiting·—·Phase 1·NCT05705570·30 enrolled
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Completed·—·Phase 1·NCT01523223·16 enrolled
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies
Completed·—·Phase 1·NCT02846935·7 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)